Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and tolerability of single and multiple intravenous doses of GIGA-2339 in adults with chronic Hepatitis B Virus HBV infection. This Phase 1 randomized, double-blind, placebo-controlled study aims to understand how GIGA-2339 behaves in the body and monitor any side effects in participants with stable HBV infection. Participants will receive either a single ascending dose or multiple ascending doses of GIGA-2339 or placebo through intravenous infusion. In Part 1, they get a single infusion on Day 1, and in Part 2, they receive multiple infusions every 4 weeks at doses determined from Part 1. The study compares these treatments to placebo to evaluate safety and pharmacokinetics. During the study, participants undergo regular blood tests to measure drug levels and monitor safety up to Day 105 for the single dose and Day 245 for multiple doses. Researchers record any adverse events and serious side effects. The study lasts until November 2028, with ongoing assessments of participants responses and tolerability throughout the dosing and follow-up periods.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.